Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $5.36 is 14.65% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 5.47||$ 9.4172|
|Low:||$ 5.2127||$ 4.675|
Company Description (as filed with the SEC)
Progenics Pharmaceuticals, Inc. and its subsidiaries (collectively the "Company," "Progenics", "we", or "us") develop innovative medicines and other technologies to target and treat cancer. Our pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA, 1095, and PSMA TTC); (2) prostate-specific membrane antigen ("PSMA") targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis technology. Our first commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant. Progenics Pharmaceuticals, Inc. was incorporated in the State of Delaware in 1986. Pipeline Our goal is to become a preeminent, patient-centric oncology company and we intend to make a difference in how patients with prostate cancer, pheochromocytoma and paraganglioma are diagnosed and treated. ... More ...
Nasdaq Official Price
Nov. 16, 2018
Nov. 16, 2018